12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
BenzingaMay 1 16:31 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersBluejay Diagnostics (NASDAQ:BJDX) shares increased by 11.0% to $0.73 during Friday's after-market session. The company's market cap stands at $1.9 million. China Pharma Holdings, Inc. Common St
BenzingaApr 26 16:31 ET
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment
Compass Therapeutics (CMPX) said Thursday that the US Food and Drug Administration has granted fast-track designation for CTX-009 in combination with paclitaxel to treat patients with metastatic or lo
MT NewswiresApr 25 13:15 ET
Compass Therapeutics' CTX-009 Gains FDA Fast Track Status
TipRanksApr 25 08:12 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
BenzingaApr 25 08:06 ET
Express News | Compass Therapeutics Inc. - Top-Line Data Readout for Companion-002, Company's Randomized Phase 2/3 BTC U.S. Study, Is Expected by End of 2024
ReutersApr 25 08:00 ET
Express News | Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of Ctx-009 in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
ReutersApr 25 08:00 ET
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics with a Buy and maintains $10 price target.
Analyst UpgradesApr 16 12:20 ET
Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)
TipRanksApr 16 10:00 ET
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics (CMPX) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment. CTX-8371 is a bispecific checkpoint inhibitor. The study includes f
MT NewswiresApr 16 08:50 ET
Express News | Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of Ctx-8371 in Patients With Solid Tumors
Moomoo 24/7Apr 16 08:00 ET
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple
GlobeNewswireApr 12 08:00 ET
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics
GlobeNewswireApr 10 08:00 ET
Buy Rating on Compass Therapeutics for Breakthrough in Resistant Tumor Treatment
TipRanksApr 10 06:27 ET
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Compass Therapeutics, Inc. (Nasdaq: CMPX) today presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9.
GlobeNewswireApr 9 12:00 ET
Compass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic Milestones
TipRanksMar 24 21:25 ET
Express News | Wedbush Reiterates Outperform on Compass Therapeutics, Maintains $8 Price Target
Moomoo 24/7Mar 22 09:58 ET
Express News | HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Maintains $10 Price Target
Moomoo 24/7Mar 21 11:15 ET
Compass Therapeutics' Strategic Advancements and Strong Financials Prompt Buy Rating
TipRanksMar 21 11:15 ET
Compass Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 344.44% HC Wainwright & Co. $10 → $10 Maintains Buy 08/03/2023 344.44% HC Wainwright & Co. → $1
BenzingaMar 21 11:07 ET
No Data
No Data